Application of cinnarizine in migraine prevention: A systematic review and meta‐analysis
- 5 October 2022
- journal article
- review article
- Published by Wiley in Pain Practice
- Vol. 22 (8) , 733-745
Abstract
Objective: To investigate and analyze the available data on the prophylactic effectiveness of cinnarizine in migraine disorder.Background: Cinnarizine has demonstrated encouraging potential in preventing the attacks of migraine. Therefore, we opted to evaluate whether its sole administration leads to positive outcomes.Methods: The PubMed, Scopus, Web of Science, and Embase databases were searched for English‐only original interventional studies published until April 2022, then screened for relevancy and eligibility. The resulting data from the included studies, including the primary (ie, headache episode frequency, intensity, duration, monthly timing, and analgesic intake frequency) and secondary (ie, reported adverse events, quality of life, and activities of daily living) outcome changes compared to placebo and active controls (e.g., sodium valproate and propranolol) were then recorded by two independent assessors. Ultimately, these data were synthesized qualitatively and quantitatively (achieved by determining the mean difference via the random‐effects model).Results: A total of 10 studies comprising seven randomized controlled trials and three quasi‐experimental studies were included. Compared to placebo, cinnarizine demonstrated significant improvements in migraine episode frequency (Mean difference = −3.10; Confidence interval = [−3.33, −2.88]; p‐value < 0.001; I2 < 0.001%), and intensity (Mean difference = −1.54; Confidence interval = [−2.08, −0.99]; p‐value < 0.001; I2 < 37.97%). Moreover, cinnarizine led to similar or better results when compared to active controls, including sodium valproate, topiramate, and propranolol.Conclusions: Cinnarizine can be considered a safe and effective medication for migraine prophylaxis. However, the relatively small sample size made reaching a definite conclusion impossible. Therefore, a higher number of randomized controlled trials are recommended to be taken place to clarify the situation further.Keywords
This publication has 36 references indexed in Scilit:
- Cinnarizine: A Promising Agent for Migraine Prevention You May Never Get the Chance to UsePediatric Neurology, 2014
- Efficacy and Safety of Cinnarizine in the Prophylaxis of Migraine in Children: A Double-Blind Placebo-Controlled Randomized TrialPediatric Neurology, 2014
- Histamine in Migraine and BrainHeadache: The Journal of Head and Face Pain, 2014
- Topiramate for the prophylaxis of episodic migraine in adultsCochrane Database of Systematic Reviews, 2013
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adultsNeurology, 2012
- Telmisartan in Migraine Prophylaxis: A Randomized, Placebo-Controlled TrialCephalalgia, 2009
- Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineursClinical Therapeutics, 2009
- Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover studyClinical Neurology and Neurosurgery, 2004
- Prophylactic Treatment of Migraine With an Angiotensin II ReceptorBlockerJAMA, 2003
- The mechanism of action of calcium antagonists relative to their clinical applications.British Journal of Clinical Pharmacology, 1986